Antibacterial FANA oligonucleotides as a novel approach for managing the Huanglongbing pathosystem
Use of a self-delivering Anti-CCL3 FANA Oligonucleotide as an innovative approach to target inflammation after Spinal Cord Injury
LET-dependent low dose and synergistic inhibition of human angiogenesis by charged particles: validation of miRNAs that drive inhibition
Endogenous antisense RNA curbs CD39 expression in Crohn’s disease
Alterations of redox and iron metabolism accompany the development of HIV latency
Seed-mediated interference of androgen signaling and survival networks induces cell death in prostate cancer cells
Cryptochromes mediate intrinsic photomechanical transduction in avian iris and somatic striated muscle
Administration of a putative pro-dopamine regulator, a neuronutrient, mitigates alcohol intake in alcohol-preferring rats
Targeting the oncogenic long non-coding RNA slncr1 by blocking its sequence- specific binding to the androgen receptor
Transdifferentiation of mouse embryonic fibroblasts into dopaminergic neurons reactivates LINE-1 repetitive elements
KCTD15 is overexpressed in human childhood B-cell acute lymphoid leukemia
Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes
Nuclear receptor 4A2 (NR4A2) is a druggable target for glioblastomas
MicroRNA‐134‐5p inhibition rescues long‐ term plasticity and synaptic tagging/ capture in an Aβ(1–42)‐induced model of Alzheimer’s disease
Human T cell differentiation negatively regulates telomerase expression resulting in reduced activation-induced proliferation and survival
The lncRNA SLNCR recruits the androgen receptor to egr1-bound genes in melanoma and inhibits expression of tumor suppressor p21
Dual mechanisms of action of self- delivering, anti-HIV-1 FANA oligonucleotides as a potential new approach to HIV therapy
Inhibition of N‐myristoyltransferase1 affects dengue virus replication
Bone marrow-specific loss of ABI1induces myeloproliferative neoplasm with features resembling human myelofibrosis
yylncT defines a class of divergently transcribed lncrnas and safeguards theTt-mediated mesodermal commitment of human PSCs
NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer
Episomal HBV persistence within transcribed host nuclear chromatin compartments involves HBx
DRR regulates AKT activation to drive brain cancer invasion
Antisense 2′-deoxy-2′-fluoroarabinonucleic acids (2′F-ANAs) antisense oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids
Studies on the hydrolytic stability of 2′-fluoroarabinonucleic acid (2′F-ANA)
2′-Deoxy-2′-fluoro-b-D-arabinonucleic acid (2′F-ANA), modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing
Characterization of antisense oligonucleotides comprised of 2′-deoxy-2′-fluoro-b-D-arabinonucleic acid (FANA): specificity, potency and duration of activity
Solanki, N., Abijo, T., Galvao, C., Darius, P., Blum, K., & Gondré-Lewis, M.C.
AUMprobes’ platform was used to detect brain dopamine D2 receptors (DRD2) by in situ hybridization. Digoxigenin (DIG)-labeled DRD2 probe from AUM BioTech was used to calculate the number of nucleus accumbens (NAc) cells expressing DRD2 mRNA.
Excessive alcohol intake is a serious but preventable public health problem in the United States and worldwide. Alcohol and other substance use disorders occur co-morbid with more generalized reward deficiency disorders, characterized by a reduction in dopamine (DA) signaling within the reward pathway, and classically associated with increased impulsivity, risk taking and subsequent drug seeking behavior. It is postulated that increasing dopamine availability and thus restoring DA homeostasis in the mesocorticolimbic system could reduce the motivation to seek and consume ethanol. Here, we treated animals with a neuro-nutrient, KB220Z also known as Synaptamine, designed to augment DA signaling.
KB220Z was administered to genetically alcohol-preferring (P) adult male and female rats by oral gavage (PO), intraperioneally (IP), or subcutaneously (SQ) for 4 consecutive days at a 3.4mL/Kg rat equivalent dose and compared to saline (SQ, IP) or water (PO) controls. Subsequent to treatment, lever pressing and consumption of 10 % ethanol or control 3% sucrose during operant responding was assessed using a drinking in the dark multiple scheduled access (DIDMSA) binge drinking protocol. Locomotor and elevated zero maze activity, and DRD2 mRNA expression via in situ hybridization (ISH) were assessed independently following 4 days of a SQ regimen of KB220Z.
KB220Z administered via IP and SQ markedly and immediately reduced binge drinking of 10 % ethanol in both male and female rats whereas PO administration took at least 3 days to decrease lever pressing for ethanol in both male and female rats. There was no effect of SQ KB220Z on 3% sucrose drinking. Elevated activity in the open field was significantly decreased, and time spent in the open arm of the EZM was moderately reduced. The regimen of SQ KB220Z did not impact the number of DRD2 punctae in neurons of the NAc, but the NAc shell expressed more DRD2 mRNA/cell than NAc core independent of KB220Z. KB220Z attenuates ethanol drinking and other RDS behaviors in P rats possibly by acting on the dopaminergic system, but not by effecting an increase in NAc DRD2 mRNA expression.Read More